PTC Therapeutics, Inc.
PTC Therapeutics, Inc. (PTCT) Stock Competitors & Peer Comparison
See (PTCT) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PTCT | $75.40 | +2.32% | 6.4B | -30.26 | -$2.54 | N/A |
| VRTX | $448.37 | +4.32% | 110.4B | 25.83 | $16.85 | N/A |
| REGN | $722.75 | +1.10% | 73.4B | 17.39 | $40.96 | +0.51% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $816.02 | +4.33% | 50.3B | 36.10 | $22.53 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $291.32 | -1.26% | 38B | 71.57 | $3.98 | N/A |
| RVMD | $144.96 | +2.22% | 30.6B | -20.27 | -$7.11 | N/A |
| UTHR | $582.48 | +3.10% | 24.2B | 21.06 | $27.06 | N/A |
| BNTX | $93.43 | -0.74% | 23.6B | -15.66 | -$5.96 | N/A |
Stock Comparison
PTCT vs VRTX Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, VRTX has a market cap of 110.4B. Regarding current trading prices, PTCT is priced at $75.40, while VRTX trades at $448.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas VRTX's P/E ratio is 25.83. In terms of profitability, PTCT's ROE is +1.00%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, PTCT is less volatile compared to VRTX. This indicates potentially lower risk in terms of short-term price fluctuations for PTCT.Check VRTX's competition here
PTCT vs REGN Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, REGN has a market cap of 73.4B. Regarding current trading prices, PTCT is priced at $75.40, while REGN trades at $722.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas REGN's P/E ratio is 17.39. In terms of profitability, PTCT's ROE is +1.00%, compared to REGN's ROE of +0.14%. Regarding short-term risk, PTCT is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check REGN's competition here
PTCT vs VRNA Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, PTCT is priced at $75.40, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas VRNA's P/E ratio is -102.80. In terms of profitability, PTCT's ROE is +1.00%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, PTCT is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check VRNA's competition here
PTCT vs ARGX Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, ARGX has a market cap of 50.3B. Regarding current trading prices, PTCT is priced at $75.40, while ARGX trades at $816.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas ARGX's P/E ratio is 36.10. In terms of profitability, PTCT's ROE is +1.00%, compared to ARGX's ROE of +0.34%. Regarding short-term risk, PTCT is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check ARGX's competition here
PTCT vs SGEN Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, PTCT is priced at $75.40, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas SGEN's P/E ratio is -57.19. In terms of profitability, PTCT's ROE is +1.00%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, PTCT is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check SGEN's competition here
PTCT vs ALNY Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, ALNY has a market cap of 38B. Regarding current trading prices, PTCT is priced at $75.40, while ALNY trades at $291.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas ALNY's P/E ratio is 71.57. In terms of profitability, PTCT's ROE is +1.00%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, PTCT is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check ALNY's competition here
PTCT vs RVMD Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, RVMD has a market cap of 30.6B. Regarding current trading prices, PTCT is priced at $75.40, while RVMD trades at $144.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas RVMD's P/E ratio is -20.27. In terms of profitability, PTCT's ROE is +1.00%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, PTCT is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check RVMD's competition here
PTCT vs UTHR Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, UTHR has a market cap of 24.2B. Regarding current trading prices, PTCT is priced at $75.40, while UTHR trades at $582.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas UTHR's P/E ratio is 21.06. In terms of profitability, PTCT's ROE is +1.00%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, PTCT is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check UTHR's competition here
PTCT vs BNTX Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, BNTX has a market cap of 23.6B. Regarding current trading prices, PTCT is priced at $75.40, while BNTX trades at $93.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas BNTX's P/E ratio is -15.66. In terms of profitability, PTCT's ROE is +1.00%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, PTCT is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check BNTX's competition here
PTCT vs INSM Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, INSM has a market cap of 22.5B. Regarding current trading prices, PTCT is priced at $75.40, while INSM trades at $115.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas INSM's P/E ratio is -18.04. In terms of profitability, PTCT's ROE is +1.00%, compared to INSM's ROE of -1.30%. Regarding short-term risk, PTCT is less volatile compared to INSM. This indicates potentially lower risk in terms of short-term price fluctuations for PTCT.Check INSM's competition here
PTCT vs RPRX Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, RPRX has a market cap of 22.2B. Regarding current trading prices, PTCT is priced at $75.40, while RPRX trades at $51.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas RPRX's P/E ratio is 27.18. In terms of profitability, PTCT's ROE is +1.00%, compared to RPRX's ROE of +0.13%. Regarding short-term risk, PTCT is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check RPRX's competition here
PTCT vs MRNA Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, MRNA has a market cap of 21B. Regarding current trading prices, PTCT is priced at $75.40, while MRNA trades at $53.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas MRNA's P/E ratio is -6.50. In terms of profitability, PTCT's ROE is +1.00%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, PTCT is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for PTCT.Check MRNA's competition here
PTCT vs ROIV Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, ROIV has a market cap of 20.7B. Regarding current trading prices, PTCT is priced at $75.40, while ROIV trades at $29.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas ROIV's P/E ratio is -24.75. In terms of profitability, PTCT's ROE is +1.00%, compared to ROIV's ROE of -0.18%. Regarding short-term risk, PTCT is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check ROIV's competition here
PTCT vs BGNE Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, PTCT is priced at $75.40, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas BGNE's P/E ratio is -22.55. In terms of profitability, PTCT's ROE is +1.00%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, PTCT is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check BGNE's competition here
PTCT vs INCY Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, INCY has a market cap of 20B. Regarding current trading prices, PTCT is priced at $75.40, while INCY trades at $99.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas INCY's P/E ratio is 14.17. In terms of profitability, PTCT's ROE is +1.00%, compared to INCY's ROE of +0.29%. Regarding short-term risk, PTCT is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check INCY's competition here
PTCT vs DNA-WT Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, PTCT is priced at $75.40, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, PTCT's ROE is +1.00%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, PTCT is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for PTCT.Check DNA-WT's competition here
PTCT vs GMAB Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, GMAB has a market cap of 16.1B. Regarding current trading prices, PTCT is priced at $75.40, while GMAB trades at $27.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas GMAB's P/E ratio is 19.83. In terms of profitability, PTCT's ROE is +1.00%, compared to GMAB's ROE of +0.21%. Regarding short-term risk, PTCT is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check GMAB's competition here
PTCT vs ASND Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, ASND has a market cap of 14.7B. Regarding current trading prices, PTCT is priced at $75.40, while ASND trades at $239.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas ASND's P/E ratio is 26.82. In terms of profitability, PTCT's ROE is +1.00%, compared to ASND's ROE of -56.42%. Regarding short-term risk, PTCT is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check ASND's competition here
PTCT vs SMMT Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, SMMT has a market cap of 14.5B. Regarding current trading prices, PTCT is priced at $75.40, while SMMT trades at $18.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas SMMT's P/E ratio is -11.74. In terms of profitability, PTCT's ROE is +1.00%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, PTCT is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for PTCT.Check SMMT's competition here
PTCT vs JAZZ Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, JAZZ has a market cap of 14B. Regarding current trading prices, PTCT is priced at $75.40, while JAZZ trades at $227.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas JAZZ's P/E ratio is 2032.82. In terms of profitability, PTCT's ROE is +1.00%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, PTCT is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check JAZZ's competition here
PTCT vs BBIO Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, BBIO has a market cap of 12.7B. Regarding current trading prices, PTCT is priced at $75.40, while BBIO trades at $65.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas BBIO's P/E ratio is -17.29. In terms of profitability, PTCT's ROE is +1.00%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, PTCT is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check BBIO's competition here
PTCT vs KRTX Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, PTCT is priced at $75.40, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas KRTX's P/E ratio is -28.09. In terms of profitability, PTCT's ROE is +1.00%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, PTCT is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check KRTX's competition here
PTCT vs EXEL Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, EXEL has a market cap of 12.5B. Regarding current trading prices, PTCT is priced at $75.40, while EXEL trades at $49.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas EXEL's P/E ratio is 16.46. In terms of profitability, PTCT's ROE is +1.00%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, PTCT is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check EXEL's competition here
PTCT vs IONS Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, IONS has a market cap of 12.5B. Regarding current trading prices, PTCT is priced at $75.40, while IONS trades at $76.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas IONS's P/E ratio is -37.50. In terms of profitability, PTCT's ROE is +1.00%, compared to IONS's ROE of -0.59%. Regarding short-term risk, PTCT is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check IONS's competition here
PTCT vs MDGL Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, MDGL has a market cap of 11.5B. Regarding current trading prices, PTCT is priced at $75.40, while MDGL trades at $505.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas MDGL's P/E ratio is -36.90. In terms of profitability, PTCT's ROE is +1.00%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, PTCT is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check MDGL's competition here
PTCT vs RNAM Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, PTCT is priced at $75.40, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas RNAM's P/E ratio is -17.39. In terms of profitability, PTCT's ROE is +1.00%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, PTCT is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check RNAM's competition here
PTCT vs AXSM Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, AXSM has a market cap of 11.1B. Regarding current trading prices, PTCT is priced at $75.40, while AXSM trades at $223.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas AXSM's P/E ratio is -58.19. In terms of profitability, PTCT's ROE is +1.00%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, PTCT is less volatile compared to AXSM. This indicates potentially lower risk in terms of short-term price fluctuations for PTCT.Check AXSM's competition here
PTCT vs ARWR Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, ARWR has a market cap of 11B. Regarding current trading prices, PTCT is priced at $75.40, while ARWR trades at $78.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas ARWR's P/E ratio is -34.25. In terms of profitability, PTCT's ROE is +1.00%, compared to ARWR's ROE of -0.56%. Regarding short-term risk, PTCT is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for PTCT.Check ARWR's competition here
PTCT vs BMRN Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, BMRN has a market cap of 10.2B. Regarding current trading prices, PTCT is priced at $75.40, while BMRN trades at $53.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas BMRN's P/E ratio is 37.83. In terms of profitability, PTCT's ROE is +1.00%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, PTCT is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check BMRN's competition here
PTCT vs RXDX Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, PTCT is priced at $75.40, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas RXDX's P/E ratio is -56.47. In terms of profitability, PTCT's ROE is +1.00%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, PTCT is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check RXDX's competition here
PTCT vs CYTK Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, CYTK has a market cap of 9.3B. Regarding current trading prices, PTCT is priced at $75.40, while CYTK trades at $74.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas CYTK's P/E ratio is -10.88. In terms of profitability, PTCT's ROE is +1.00%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, PTCT is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check CYTK's competition here
PTCT vs KRYS Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, KRYS has a market cap of 9.2B. Regarding current trading prices, PTCT is priced at $75.40, while KRYS trades at $310.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas KRYS's P/E ratio is 41.94. In terms of profitability, PTCT's ROE is +1.00%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, PTCT is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check KRYS's competition here
PTCT vs IMGN Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, PTCT is priced at $75.40, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas IMGN's P/E ratio is -111.55. In terms of profitability, PTCT's ROE is +1.00%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, PTCT is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check IMGN's competition here
PTCT vs IBRX Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, IBRX has a market cap of 8.5B. Regarding current trading prices, PTCT is priced at $75.40, while IBRX trades at $8.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas IBRX's P/E ratio is -9.54. In terms of profitability, PTCT's ROE is +1.00%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, PTCT is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for PTCT.Check IBRX's competition here
PTCT vs BPMC Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, PTCT is priced at $75.40, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas BPMC's P/E ratio is -51.58. In terms of profitability, PTCT's ROE is +1.00%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, PTCT is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check BPMC's competition here
PTCT vs CERE Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, PTCT is priced at $75.40, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas CERE's P/E ratio is -16.47. In terms of profitability, PTCT's ROE is +1.00%, compared to CERE's ROE of -0.72%. Regarding short-term risk, PTCT is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check CERE's competition here
PTCT vs ABVX Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, ABVX has a market cap of 8B. Regarding current trading prices, PTCT is priced at $75.40, while ABVX trades at $121.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas ABVX's P/E ratio is -21.54. In terms of profitability, PTCT's ROE is +1.00%, compared to ABVX's ROE of -1.59%. Regarding short-term risk, PTCT is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check ABVX's competition here
PTCT vs HALO Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, HALO has a market cap of 7.9B. Regarding current trading prices, PTCT is priced at $75.40, while HALO trades at $71.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas HALO's P/E ratio is 25.94. In terms of profitability, PTCT's ROE is +1.00%, compared to HALO's ROE of +0.93%. Regarding short-term risk, PTCT is less volatile compared to HALO. This indicates potentially lower risk in terms of short-term price fluctuations for PTCT.Check HALO's competition here
PTCT vs PCVX Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, PCVX has a market cap of 7.8B. Regarding current trading prices, PTCT is priced at $75.40, while PCVX trades at $53.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas PCVX's P/E ratio is -7.84. In terms of profitability, PTCT's ROE is +1.00%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, PTCT is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for PTCT.Check PCVX's competition here
PTCT vs NUVL Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, NUVL has a market cap of 7.7B. Regarding current trading prices, PTCT is priced at $75.40, while NUVL trades at $102.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas NUVL's P/E ratio is -17.25. In terms of profitability, PTCT's ROE is +1.00%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, PTCT is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check NUVL's competition here
PTCT vs MTSR Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, PTCT is priced at $75.40, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas MTSR's P/E ratio is -23.58. In terms of profitability, PTCT's ROE is +1.00%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, PTCT is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check MTSR's competition here
PTCT vs TECH Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, TECH has a market cap of 7.4B. Regarding current trading prices, PTCT is priced at $75.40, while TECH trades at $47.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas TECH's P/E ratio is 67.74. In terms of profitability, PTCT's ROE is +1.00%, compared to TECH's ROE of +0.05%. Regarding short-term risk, PTCT is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for PTCT.Check TECH's competition here
PTCT vs PRAX Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, PRAX has a market cap of 7B. Regarding current trading prices, PTCT is priced at $75.40, while PRAX trades at $334.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas PRAX's P/E ratio is -24.76. In terms of profitability, PTCT's ROE is +1.00%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, PTCT is less volatile compared to PRAX. This indicates potentially lower risk in terms of short-term price fluctuations for PTCT.Check PRAX's competition here
PTCT vs KYMR Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, KYMR has a market cap of 6.9B. Regarding current trading prices, PTCT is priced at $75.40, while KYMR trades at $82.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas KYMR's P/E ratio is -23.49. In terms of profitability, PTCT's ROE is +1.00%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, PTCT is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check KYMR's competition here
PTCT vs MRUS Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, PTCT is priced at $75.40, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas MRUS's P/E ratio is -17.05. In terms of profitability, PTCT's ROE is +1.00%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, PTCT is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check MRUS's competition here
PTCT vs ACLX Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, PTCT is priced at $75.40, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas ACLX's P/E ratio is -28.27. In terms of profitability, PTCT's ROE is +1.00%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, PTCT is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check ACLX's competition here
PTCT vs PTGX Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, PTGX has a market cap of 6.7B. Regarding current trading prices, PTCT is priced at $75.40, while PTGX trades at $98.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas PTGX's P/E ratio is -57.18. In terms of profitability, PTCT's ROE is +1.00%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, PTCT is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for PTCT.Check PTGX's competition here
PTCT vs TGTX Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, TGTX has a market cap of 6.6B. Regarding current trading prices, PTCT is priced at $75.40, while TGTX trades at $42.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas TGTX's P/E ratio is 15.08. In terms of profitability, PTCT's ROE is +1.00%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, PTCT is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check TGTX's competition here
PTCT vs RETA Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, PTCT is priced at $75.40, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas RETA's P/E ratio is -66.29. In terms of profitability, PTCT's ROE is +1.00%, compared to RETA's ROE of +0.47%. Regarding short-term risk, PTCT is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check RETA's competition here
PTCT vs CNTA Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, CNTA has a market cap of 6.1B. Regarding current trading prices, PTCT is priced at $75.40, while CNTA trades at $39.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas CNTA's P/E ratio is -22.24. In terms of profitability, PTCT's ROE is +1.00%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, PTCT is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check CNTA's competition here
PTCT vs BLTE Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, BLTE has a market cap of 6.1B. Regarding current trading prices, PTCT is priced at $75.40, while BLTE trades at $155.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas BLTE's P/E ratio is -65.79. In terms of profitability, PTCT's ROE is +1.00%, compared to BLTE's ROE of -0.23%. Regarding short-term risk, PTCT is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check BLTE's competition here
PTCT vs CELC Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, CELC has a market cap of 6.1B. Regarding current trading prices, PTCT is priced at $75.40, while CELC trades at $123.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas CELC's P/E ratio is -33.15. In terms of profitability, PTCT's ROE is +1.00%, compared to CELC's ROE of -2.03%. Regarding short-term risk, PTCT is less volatile compared to CELC. This indicates potentially lower risk in terms of short-term price fluctuations for PTCT.Check CELC's competition here
PTCT vs RYTM Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, RYTM has a market cap of 6B. Regarding current trading prices, PTCT is priced at $75.40, while RYTM trades at $91.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas RYTM's P/E ratio is -27.99. In terms of profitability, PTCT's ROE is +1.00%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, PTCT is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check RYTM's competition here
PTCT vs IMVT Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, IMVT has a market cap of 5.9B. Regarding current trading prices, PTCT is priced at $75.40, while IMVT trades at $28.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas IMVT's P/E ratio is -10.88. In terms of profitability, PTCT's ROE is +1.00%, compared to IMVT's ROE of -0.66%. Regarding short-term risk, PTCT is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for PTCT.Check IMVT's competition here
PTCT vs ALKS Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, ALKS has a market cap of 5.9B. Regarding current trading prices, PTCT is priced at $75.40, while ALKS trades at $38.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas ALKS's P/E ratio is 39.41. In terms of profitability, PTCT's ROE is +1.00%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, PTCT is less volatile compared to ALKS. This indicates potentially lower risk in terms of short-term price fluctuations for PTCT.Check ALKS's competition here
PTCT vs CGON Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, CGON has a market cap of 5.9B. Regarding current trading prices, PTCT is priced at $75.40, while CGON trades at $71.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas CGON's P/E ratio is -29.62. In terms of profitability, PTCT's ROE is +1.00%, compared to CGON's ROE of -0.23%. Regarding short-term risk, PTCT is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for PTCT.Check CGON's competition here
PTCT vs COGT Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, COGT has a market cap of 5.8B. Regarding current trading prices, PTCT is priced at $75.40, while COGT trades at $34.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas COGT's P/E ratio is -15.71. In terms of profitability, PTCT's ROE is +1.00%, compared to COGT's ROE of -0.83%. Regarding short-term risk, PTCT is less volatile compared to COGT. This indicates potentially lower risk in terms of short-term price fluctuations for PTCT.Check COGT's competition here
PTCT vs SRRK Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, SRRK has a market cap of 5.8B. Regarding current trading prices, PTCT is priced at $75.40, while SRRK trades at $48.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas SRRK's P/E ratio is -14.01. In terms of profitability, PTCT's ROE is +1.00%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, PTCT is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check SRRK's competition here
PTCT vs CDTX Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, PTCT is priced at $75.40, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas CDTX's P/E ratio is -19.77. In terms of profitability, PTCT's ROE is +1.00%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, PTCT is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check CDTX's competition here
PTCT vs ABCM Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, PTCT is priced at $75.40, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, PTCT's ROE is +1.00%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, PTCT is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check ABCM's competition here
PTCT vs ISEE Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, PTCT is priced at $75.40, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas ISEE's P/E ratio is -22.44. In terms of profitability, PTCT's ROE is +1.00%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, PTCT is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check ISEE's competition here
PTCT vs CORT Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, CORT has a market cap of 5.5B. Regarding current trading prices, PTCT is priced at $75.40, while CORT trades at $51.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas CORT's P/E ratio is 146.29. In terms of profitability, PTCT's ROE is +1.00%, compared to CORT's ROE of +0.08%. Regarding short-term risk, PTCT is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check CORT's competition here
PTCT vs MIRM Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, MIRM has a market cap of 5.3B. Regarding current trading prices, PTCT is priced at $75.40, while MIRM trades at $106.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas MIRM's P/E ratio is -7.81. In terms of profitability, PTCT's ROE is +1.00%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, PTCT is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check MIRM's competition here
PTCT vs APLS Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, PTCT is priced at $75.40, while APLS trades at $41.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas APLS's P/E ratio is 38.34. In terms of profitability, PTCT's ROE is +1.00%, compared to APLS's ROE of +0.40%. Regarding short-term risk, PTCT is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check APLS's competition here
PTCT vs APGE Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, APGE has a market cap of 5.2B. Regarding current trading prices, PTCT is priced at $75.40, while APGE trades at $82.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas APGE's P/E ratio is -20.05. In terms of profitability, PTCT's ROE is +1.00%, compared to APGE's ROE of -0.24%. Regarding short-term risk, PTCT is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for PTCT.Check APGE's competition here
PTCT vs CRSP Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, CRSP has a market cap of 5.2B. Regarding current trading prices, PTCT is priced at $75.40, while CRSP trades at $52.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas CRSP's P/E ratio is -8.75. In terms of profitability, PTCT's ROE is +1.00%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, PTCT is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for PTCT.Check CRSP's competition here
PTCT vs FBIOX Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, FBIOX has a market cap of 5.2B. Regarding current trading prices, PTCT is priced at $75.40, while FBIOX trades at $25.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas FBIOX's P/E ratio is N/A. In terms of profitability, PTCT's ROE is +1.00%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, PTCT is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check FBIOX's competition here
PTCT vs TERN Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, PTCT is priced at $75.40, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas TERN's P/E ratio is -51.41. In terms of profitability, PTCT's ROE is +1.00%, compared to TERN's ROE of -0.20%. Regarding short-term risk, PTCT is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check TERN's competition here
PTCT vs LEGN Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, LEGN has a market cap of 4.7B. Regarding current trading prices, PTCT is priced at $75.40, while LEGN trades at $28.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas LEGN's P/E ratio is -15.79. In terms of profitability, PTCT's ROE is +1.00%, compared to LEGN's ROE of -0.29%. Regarding short-term risk, PTCT is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for PTCT.Check LEGN's competition here
PTCT vs LQDA Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, LQDA has a market cap of 4.7B. Regarding current trading prices, PTCT is priced at $75.40, while LQDA trades at $55.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas LQDA's P/E ratio is -66.41. In terms of profitability, PTCT's ROE is +1.00%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, PTCT is less volatile compared to LQDA. This indicates potentially lower risk in terms of short-term price fluctuations for PTCT.Check LQDA's competition here
PTCT vs NAMS Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, NAMS has a market cap of 4.6B. Regarding current trading prices, PTCT is priced at $75.40, while NAMS trades at $38.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas NAMS's P/E ratio is -22.24. In terms of profitability, PTCT's ROE is +1.00%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, PTCT is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for PTCT.Check NAMS's competition here
PTCT vs SYRE Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, SYRE has a market cap of 4.6B. Regarding current trading prices, PTCT is priced at $75.40, while SYRE trades at $74.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas SYRE's P/E ratio is -36.05. In terms of profitability, PTCT's ROE is +1.00%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, PTCT is less volatile compared to SYRE. This indicates potentially lower risk in terms of short-term price fluctuations for PTCT.Check SYRE's competition here
PTCT vs FOLD Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, PTCT is priced at $75.40, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas FOLD's P/E ratio is -161.00. In terms of profitability, PTCT's ROE is +1.00%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, PTCT is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check FOLD's competition here
PTCT vs CAI Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, CAI has a market cap of 4.5B. Regarding current trading prices, PTCT is priced at $75.40, while CAI trades at $16.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas CAI's P/E ratio is -5.65. In terms of profitability, PTCT's ROE is +1.00%, compared to CAI's ROE of +0.06%. Regarding short-term risk, PTCT is less volatile compared to CAI. This indicates potentially lower risk in terms of short-term price fluctuations for PTCT.Check CAI's competition here
PTCT vs AKRO Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, PTCT is priced at $75.40, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas AKRO's P/E ratio is -14.57. In terms of profitability, PTCT's ROE is +1.00%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, PTCT is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check AKRO's competition here
PTCT vs MANE Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, MANE has a market cap of 4.5B. Regarding current trading prices, PTCT is priced at $75.40, while MANE trades at $103.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas MANE's P/E ratio is -45.56. In terms of profitability, PTCT's ROE is +1.00%, compared to MANE's ROE of -0.76%. Regarding short-term risk, PTCT is less volatile compared to MANE. This indicates potentially lower risk in terms of short-term price fluctuations for PTCT.Check MANE's competition here
PTCT vs ALPN Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, PTCT is priced at $75.40, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas ALPN's P/E ratio is -101.52. In terms of profitability, PTCT's ROE is +1.00%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, PTCT is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check ALPN's competition here
PTCT vs LGND Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, LGND has a market cap of 4.4B. Regarding current trading prices, PTCT is priced at $75.40, while LGND trades at $224.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas LGND's P/E ratio is 28.78. In terms of profitability, PTCT's ROE is +1.00%, compared to LGND's ROE of +0.16%. Regarding short-term risk, PTCT is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check LGND's competition here
PTCT vs XENE Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, XENE has a market cap of 4.4B. Regarding current trading prices, PTCT is priced at $75.40, while XENE trades at $55.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas XENE's P/E ratio is -11.87. In terms of profitability, PTCT's ROE is +1.00%, compared to XENE's ROE of -0.49%. Regarding short-term risk, PTCT is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check XENE's competition here
PTCT vs KNSA Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, KNSA has a market cap of 4.4B. Regarding current trading prices, PTCT is priced at $75.40, while KNSA trades at $59.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas KNSA's P/E ratio is 64.14. In terms of profitability, PTCT's ROE is +1.00%, compared to KNSA's ROE of +0.13%. Regarding short-term risk, PTCT is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check KNSA's competition here
PTCT vs OPT Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, PTCT is priced at $75.40, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas OPT's P/E ratio is -1.52. In terms of profitability, PTCT's ROE is +1.00%, compared to OPT's ROE of +0.88%. Regarding short-term risk, PTCT is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check OPT's competition here
PTCT vs MRTX Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, PTCT is priced at $75.40, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas MRTX's P/E ratio is -4.82. In terms of profitability, PTCT's ROE is +1.00%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, PTCT is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check MRTX's competition here
PTCT vs TVTX Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, TVTX has a market cap of 4B. Regarding current trading prices, PTCT is priced at $75.40, while TVTX trades at $42.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas TVTX's P/E ratio is -87.02. In terms of profitability, PTCT's ROE is +1.00%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, PTCT is more volatile compared to TVTX. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check TVTX's competition here
PTCT vs CRNX Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, CRNX has a market cap of 3.9B. Regarding current trading prices, PTCT is priced at $75.40, while CRNX trades at $36.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas CRNX's P/E ratio is -7.11. In terms of profitability, PTCT's ROE is +1.00%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, PTCT is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for PTCT.Check CRNX's competition here
PTCT vs CPRX Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, CPRX has a market cap of 3.8B. Regarding current trading prices, PTCT is priced at $75.40, while CPRX trades at $31.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas CPRX's P/E ratio is 18.54. In terms of profitability, PTCT's ROE is +1.00%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, PTCT is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check CPRX's competition here
PTCT vs RYZB Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, PTCT is priced at $75.40, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas RYZB's P/E ratio is -57.86. In terms of profitability, PTCT's ROE is +1.00%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, PTCT is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check RYZB's competition here
PTCT vs ACAD Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, ACAD has a market cap of 3.7B. Regarding current trading prices, PTCT is priced at $75.40, while ACAD trades at $21.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas ACAD's P/E ratio is 9.86. In terms of profitability, PTCT's ROE is +1.00%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, PTCT is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check ACAD's competition here
PTCT vs CBAY Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, PTCT is priced at $75.40, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas CBAY's P/E ratio is -32.81. In terms of profitability, PTCT's ROE is +1.00%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, PTCT is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check CBAY's competition here
PTCT vs EWTX Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, EWTX has a market cap of 3.7B. Regarding current trading prices, PTCT is priced at $75.40, while EWTX trades at $33.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas EWTX's P/E ratio is -20.82. In terms of profitability, PTCT's ROE is +1.00%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, PTCT is more volatile compared to EWTX. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check EWTX's competition here
PTCT vs VKTX Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, VKTX has a market cap of 3.7B. Regarding current trading prices, PTCT is priced at $75.40, while VKTX trades at $31.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas VKTX's P/E ratio is -7.64. In terms of profitability, PTCT's ROE is +1.00%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, PTCT is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check VKTX's competition here
PTCT vs TLX Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, TLX has a market cap of 3.7B. Regarding current trading prices, PTCT is priced at $75.40, while TLX trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas TLX's P/E ratio is -541.50. In terms of profitability, PTCT's ROE is +1.00%, compared to TLX's ROE of -0.02%. Regarding short-term risk, PTCT is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check TLX's competition here
PTCT vs DNTH Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, DNTH has a market cap of 3.6B. Regarding current trading prices, PTCT is priced at $75.40, while DNTH trades at $86.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas DNTH's P/E ratio is -20.60. In terms of profitability, PTCT's ROE is +1.00%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, PTCT is more volatile compared to DNTH. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check DNTH's competition here
PTCT vs SWTX Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, PTCT is priced at $75.40, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas SWTX's P/E ratio is -13.78. In terms of profitability, PTCT's ROE is +1.00%, compared to SWTX's ROE of -0.36%. Regarding short-term risk, PTCT is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check SWTX's competition here
PTCT vs NAMSW Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, NAMSW has a market cap of 3.4B. Regarding current trading prices, PTCT is priced at $75.40, while NAMSW trades at $27.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas NAMSW's P/E ratio is N/A. In terms of profitability, PTCT's ROE is +1.00%, compared to NAMSW's ROE of -0.30%. Regarding short-term risk, PTCT is less volatile compared to NAMSW. This indicates potentially lower risk in terms of short-term price fluctuations for PTCT.Check NAMSW's competition here
PTCT vs BEAM Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, BEAM has a market cap of 3.3B. Regarding current trading prices, PTCT is priced at $75.40, while BEAM trades at $31.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas BEAM's P/E ratio is -64.80. In terms of profitability, PTCT's ROE is +1.00%, compared to BEAM's ROE of -0.06%. Regarding short-term risk, PTCT is more volatile compared to BEAM. This indicates potentially higher risk in terms of short-term price fluctuations for PTCT.Check BEAM's competition here
PTCT vs ERAS Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, ERAS has a market cap of 3.2B. Regarding current trading prices, PTCT is priced at $75.40, while ERAS trades at $10.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas ERAS's P/E ratio is -23.73. In terms of profitability, PTCT's ROE is +1.00%, compared to ERAS's ROE of -0.34%. Regarding short-term risk, PTCT is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for PTCT.Check ERAS's competition here
PTCT vs VCYT Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, VCYT has a market cap of 3.2B. Regarding current trading prices, PTCT is priced at $75.40, while VCYT trades at $39.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas VCYT's P/E ratio is 36.77. In terms of profitability, PTCT's ROE is +1.00%, compared to VCYT's ROE of +0.07%. Regarding short-term risk, PTCT is less volatile compared to VCYT. This indicates potentially lower risk in terms of short-term price fluctuations for PTCT.Check VCYT's competition here
PTCT vs DNLI Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, DNLI has a market cap of 3.1B. Regarding current trading prices, PTCT is priced at $75.40, while DNLI trades at $19.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas DNLI's P/E ratio is -6.83. In terms of profitability, PTCT's ROE is +1.00%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, PTCT is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for PTCT.Check DNLI's competition here
PTCT vs DYN Comparison May 2026
PTCT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 6.4B. In comparison, DYN has a market cap of 3B. Regarding current trading prices, PTCT is priced at $75.40, while DYN trades at $18.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -30.26, whereas DYN's P/E ratio is -5.32. In terms of profitability, PTCT's ROE is +1.00%, compared to DYN's ROE of -0.58%. Regarding short-term risk, PTCT is less volatile compared to DYN. This indicates potentially lower risk in terms of short-term price fluctuations for PTCT.Check DYN's competition here